Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Aileron Therapeutics Inc
ALRN | US
3.57
USD-0.05
-1.38%
ALRN | US
About Aileron Therapeutics Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
21/10/2024
Close
3.57
Open
3.62
High
3.70
Low
3.56
Aileron Therapeutics Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924 which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine or Ara-C in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics Inc. and changed its name to Aileron Therapeutics Inc. in February 2007. Aileron Therapeutics Inc. was incorporated in 2001 and is headquartered in Boston Massachusetts.
View LessALRN | US
Risk
83.4
Sharpe
1.05
Luna's Score
45/100
Recommendation
Sell
Luna says (ALRN | US)
What's Working
Value Stock (Price to Book < 3)
What's not Working
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
61.6%1 month
83.4%3 months
111.8%6 months
88.0%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
1.43
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-0.64
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-25.40M
MarketCap
77.35M
MarketCap(USD)
77.35M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-44.32
Short ratio
2.88
Short perc.
1.38
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.51
Range1M
0.97
Range3M
2.22
Volumes: Market Activity
Rel. volume
0.88
Price X volume
120.83K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.64 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 1.43 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 111.79 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 77.35M | 3.66B | Emerging |
